查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1599235

静脉血栓栓塞症治疗药物市场：依药物类别、器材、应用、最终用途 - 全球预测 2025-2030

Venous Thromboembolism Therapeutic Market by Drug Class (Direct Thrombin Inhibitors, Factor XA Inhibitors, Heparin), Device (Compression System, IVC Filters, Stockings), Application, End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

静脉血栓栓塞症治疗市场2023年估值为24亿美元，预计2024年将达25.4亿美元，复合年增长率为5.84%，预计到2030年将达到35.7亿美元。

静脉血栓栓塞症(VTE) 医学包括专门针对静脉内血栓的治疗和预防措施，例如深层静脉栓塞症(DVT) 和肺动脉栓塞(PE)。 VTE 药物市场主要是由于生活方式的改变、肥胖症的增加和人口老化而导致这些疾病的发生率不断增加。由于其潜在的危及生命的性质，对有效 VTE 管理的需求是显而易见的，这进一步增加了医疗机构的关键需求。治疗药物用途广泛，包括抗凝血剂、血栓溶解剂和机械方法，主要最终使用者为医院、专科诊所和门诊医疗机构。直接口服抗凝血剂 (DOAC) 等近期创新技术因其比传统Warfarin疗法更高的安全性和易用性而不断增加，带来了利润丰厚的市场机会。此外，人们对基因疗法和个人化医疗等新型疗法的认识不断提高，并取得了进步，为进一步成长提供了前景。然而，成长受到严格监管要求、高昂治疗成本以及与领先治疗方法相关的潜在副作用等限制因素的挑战。竞争方面，大药专利到期后学名药厂商的进入也是价格方面的一大问题。创新的最佳途径在于开发更安全、更有效、副作用更少的治疗方法，并应用人工智慧来预测患者特定的治疗反应。此外，研究 VTE 的遗传基础以开发标靶治疗可能会促进未来的成长。为公司提供的策略建议包括投资创新疗法的研发、扩大病患教育计画以加强早期检测和预防，以及建立策略联盟以提高市场渗透率。 VTE 治疗市场是动态的，其特点是不断发展的技术和标准，反映了该医疗保健行业的复杂性和潜力。

主要市场统计
基准年[2023] 24亿美元
预测年份 [2024] 25.4亿美元
预测年份 [2030] 35.7亿美元
复合年增长率（%） 5.84%

市场动态：快速发展的静脉血栓栓塞症药物市场的关键市场洞察

供需的动态交互作用正在改变静脉血栓栓塞症药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 静脉血栓栓塞症的发生率增加
    • 髋关节和关节重建置换术等外科手术的增加
    • 提高患者对 VTE 治疗的认识
  • 市场限制因素
    • 与 VTE 药物相关的高治疗成本和副作用
  • 市场机会
    • 开发高效率、先进的技术
    • 政府针对静脉血栓栓塞症治疗的倡议
  • 市场挑战
    • 严格而复杂的监管程序

波特五力：驾驭静脉血栓栓塞症药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对静脉血栓栓塞症药物市场的影响

外部宏观环境因素在塑造静脉血栓栓塞症治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解静脉血栓栓塞症治疗药物市场的竞争状况

静脉血栓栓塞症治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵静脉血栓栓塞症治疗市场供应商的绩效评估

FPNV定位矩阵是评估静脉血栓栓塞症治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘静脉血栓栓塞症治疗药物市场的成功之路

对静脉血栓栓塞症治疗药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 静脉血栓栓塞症的发生率增加
      • 髋关节和膝关节置换手术等外科手术的增加
      • 提高患者对 VTE 治疗的认识
    • 抑制因素
      • VTE 治疗药物相关的高治疗成本和副作用
    • 机会
      • 开发高效率、先进的技术
      • 政府关于静脉血栓栓塞症治疗的倡议
    • 任务
      • 严格而复杂的监管程序
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章静脉血栓栓塞症治疗药物市场（依药物类别）

  • 直接凝血酶抑制剂
  • XA因子抑制剂
  • 肝素
  • 维生素K拮抗剂

第七章静脉血栓栓塞症治疗药物市场：依设备分类

  • 压缩系统
  • 下腔静脉过滤器
  • 丝袜
  • 血栓清除系统

第八章静脉血栓栓塞症治疗药物市场：依应用分类

  • 深层静脉栓塞症
  • 肺动脉栓塞

第九章静脉血栓栓塞症治疗药物市场：依最终用途分类

  • 导管实验室
  • 医院

第十章 北美及南美静脉血栓栓塞症药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太静脉静脉血栓栓塞症药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲静脉静脉血栓栓塞症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AngioDynamics, Inc.
  • Argon Medical Devices, Inc.
  • Arjo AB
  • Bio Compression Systems
  • BioInvent International AB
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Cardinal Health, Inc.
  • Cook Group Incorporated
  • DAIICHI SANKYO COMPANY, LIMITED
  • eXIthera Pharmaceuticals
  • Koninklijke Philips NV
  • Medtronic PLC
  • Sanofi SA
Product Code: MRR-034B50030388

The Venous Thromboembolism Therapeutic Market was valued at USD 2.40 billion in 2023, expected to reach USD 2.54 billion in 2024, and is projected to grow at a CAGR of 5.84%, to USD 3.57 billion by 2030.

Venous Thromboembolism (VTE) Therapeutics encompass treatments and preventative measures for managing blood clots in the vein, notably types like deep vein thrombosis (DVT) and pulmonary embolism (PE). The market for VTE therapeutics is driven by the rising incidence of these conditions due largely to lifestyle changes, increasing cases of obesity, and a growing aging population. The necessity of effective VTE management is evident in its potential life-threatening nature, compounding its critical demand in healthcare settings. Therapeutics applications span across anticoagulants, thrombolytics, and mechanical methods, with hospitals, specialized clinics, and outpatient healthcare facilities being the principal end-users. Recent innovations such as direct oral anticoagulants (DOACs) are increasing due to their enhanced safety profile and ease of use over traditional warfarin treatments, showcasing lucrative market opportunities. Moreover, increasing awareness and the evolution of novel therapies, like gene therapies and personalized medicines, present further growth prospects. However, growth is challenged by limitations such as stringent regulatory requirements, high costs of treatment, and potential side effects related to key therapeutic regimes. In the competitive market landscape, entry by generics manufacturers post-patent expiration of key drugs also poses significant pricing challenges. Optimal innovation avenues lie in the development of safer, more effective treatment modalities with fewer side effects and the application of artificial intelligence in predicting patient-specific therapy responses. Additionally, research into the genetic basis of VTE to develop targeted treatments could propel future growth. Strategic recommendations for businesses include investing in R&D for innovative therapeutics, expanding patient education programs to enhance early detection and prevention, and forming strategic alliances to broaden market penetration. The VTE therapeutic market is dynamic, marked by evolving technologies and standards, reflecting both the complexity and potential within this healthcare sector.

KEY MARKET STATISTICS
Base Year [2023] USD 2.40 billion
Estimated Year [2024] USD 2.54 billion
Forecast Year [2030] USD 3.57 billion
CAGR (%) 5.84%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Venous Thromboembolism Therapeutic Market

The Venous Thromboembolism Therapeutic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Escalating rate of venous thromboembolism
    • Increasing surgical procedures such as hip and knee replacements
    • Increase in patient awareness towards VTE treatment
  • Market Restraints
    • High treatment cost and side effects associated with VTE drugs
  • Market Opportunities
    • Development of efficient and advanced technology
    • Government initiatives for venous thromboembolism treatments
  • Market Challenges
    • Stringent and complex regulatory procedures

Porter's Five Forces: A Strategic Tool for Navigating the Venous Thromboembolism Therapeutic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Venous Thromboembolism Therapeutic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Venous Thromboembolism Therapeutic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Venous Thromboembolism Therapeutic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Venous Thromboembolism Therapeutic Market

A detailed market share analysis in the Venous Thromboembolism Therapeutic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Venous Thromboembolism Therapeutic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Venous Thromboembolism Therapeutic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Venous Thromboembolism Therapeutic Market

A strategic analysis of the Venous Thromboembolism Therapeutic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Venous Thromboembolism Therapeutic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AngioDynamics, Inc., Argon Medical Devices, Inc., Arjo AB, Bio Compression Systems, BioInvent International AB, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Company, Cardinal Health, Inc., Cook Group Incorporated, DAIICHI SANKYO COMPANY, LIMITED, eXIthera Pharmaceuticals, Koninklijke Philips N.V., Medtronic PLC, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Venous Thromboembolism Therapeutic Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Direct Thrombin Inhibitors, Factor XA Inhibitors, Heparin, and Vitamin K Antagonists.
  • Based on Device, market is studied across Compression System, IVC Filters, Stockings, and Thrombectomy Systems.
  • Based on Application, market is studied across Deep vein Thrombosis and Pulmonary Embolism.
  • Based on End-use, market is studied across Catheterization Laboratories and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Escalating rate of venous thromboembolism
      • 5.1.1.2. Increasing surgical procedures such as hip and knee replacements
      • 5.1.1.3. Increase in patient awareness towards VTE treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment cost and side effects associated with VTE drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of efficient and advanced technology
      • 5.1.3.2. Government initiatives for venous thromboembolism treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent and complex regulatory procedures
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Venous Thromboembolism Therapeutic Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Direct Thrombin Inhibitors
  • 6.3. Factor XA Inhibitors
  • 6.4. Heparin
  • 6.5. Vitamin K Antagonists

7. Venous Thromboembolism Therapeutic Market, by Device

  • 7.1. Introduction
  • 7.2. Compression System
  • 7.3. IVC Filters
  • 7.4. Stockings
  • 7.5. Thrombectomy Systems

8. Venous Thromboembolism Therapeutic Market, by Application

  • 8.1. Introduction
  • 8.2. Deep vein Thrombosis
  • 8.3. Pulmonary Embolism

9. Venous Thromboembolism Therapeutic Market, by End-use

  • 9.1. Introduction
  • 9.2. Catheterization Laboratories
  • 9.3. Hospitals

10. Americas Venous Thromboembolism Therapeutic Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Venous Thromboembolism Therapeutic Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Venous Thromboembolism Therapeutic Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AngioDynamics, Inc.
  • 3. Argon Medical Devices, Inc.
  • 4. Arjo AB
  • 5. Bio Compression Systems
  • 6. BioInvent International AB
  • 7. Boehringer Ingelheim International GmbH
  • 8. Boston Scientific Corporation
  • 9. Bristol-Myers Squibb Company
  • 10. Cardinal Health, Inc.
  • 11. Cook Group Incorporated
  • 12. DAIICHI SANKYO COMPANY, LIMITED
  • 13. eXIthera Pharmaceuticals
  • 14. Koninklijke Philips N.V.
  • 15. Medtronic PLC
  • 16. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET RESEARCH PROCESS
  • FIGURE 2. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET DYNAMICS
  • TABLE 7. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DIRECT THROMBIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY FACTOR XA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HEPARIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY VITAMIN K ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COMPRESSION SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY IVC FILTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY STOCKINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY THROMBECTOMY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY CATHETERIZATION LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 191. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. VENOUS THROMBOEMBOLISM THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, 2023